A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice

Abstract Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic fever disease in humans. Currently, no licensed CCHF vaccines exist, and the protective epitopes remain unclear. Previously, we tested a DNA vaccine expressing the M-segment glycoprotein precu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	John J. Suschak, Joseph W. Golden, Collin J. Fitzpatrick, Charles J. Shoemaker, Catherine V. Badger, Connie S. Schmaljohn, Aura R. Garrison
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/202859103c404a889b8935a4b09444ed
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:202859103c404a889b8935a4b09444ed
record_format	dspace
spelling	oai:doaj.org-article:202859103c404a889b8935a4b09444ed2021-12-02T18:01:29ZA CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice10.1038/s41541-021-00293-92059-0105https://doaj.org/article/202859103c404a889b8935a4b09444ed2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00293-9https://doaj.org/toc/2059-0105Abstract Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic fever disease in humans. Currently, no licensed CCHF vaccines exist, and the protective epitopes remain unclear. Previously, we tested a DNA vaccine expressing the M-segment glycoprotein precursor gene of the laboratory CCHFV strain IbAr 10200 (CCHFV-M10200). CCHFV-M10200 provided >60% protection against homologous CCHFV-IbAr 10200 challenge in mice. Here, we report that increasing the dose of CCHFV-M10200 provides complete protection from homologous CCHFV challenge in mice, and significant (80%) protection from challenge with the clinically relevant heterologous strain CCHFV-Afg09-2990. We also report complete protection from CCHFV-Afg09-2990 challenge following vaccination with a CCHFV-Afg09-2990 M-segment DNA vaccine (CCHFV-MAfg09). Finally, we show that the non-structural M-segment protein, GP38, influences CCHF vaccine immunogenicity and provides significant protection from homologous CCHFV challenge. Our results demonstrate that M-segment DNA vaccines elicit protective CCHF immunity and further illustrate the immunorelevance of GP38.John J. SuschakJoseph W. GoldenCollin J. FitzpatrickCharles J. ShoemakerCatherine V. BadgerConnie S. SchmaljohnAura R. GarrisonNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 John J. Suschak Joseph W. Golden Collin J. Fitzpatrick Charles J. Shoemaker Catherine V. Badger Connie S. Schmaljohn Aura R. Garrison A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice
description	Abstract Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic fever disease in humans. Currently, no licensed CCHF vaccines exist, and the protective epitopes remain unclear. Previously, we tested a DNA vaccine expressing the M-segment glycoprotein precursor gene of the laboratory CCHFV strain IbAr 10200 (CCHFV-M10200). CCHFV-M10200 provided >60% protection against homologous CCHFV-IbAr 10200 challenge in mice. Here, we report that increasing the dose of CCHFV-M10200 provides complete protection from homologous CCHFV challenge in mice, and significant (80%) protection from challenge with the clinically relevant heterologous strain CCHFV-Afg09-2990. We also report complete protection from CCHFV-Afg09-2990 challenge following vaccination with a CCHFV-Afg09-2990 M-segment DNA vaccine (CCHFV-MAfg09). Finally, we show that the non-structural M-segment protein, GP38, influences CCHF vaccine immunogenicity and provides significant protection from homologous CCHFV challenge. Our results demonstrate that M-segment DNA vaccines elicit protective CCHF immunity and further illustrate the immunorelevance of GP38.
format	article
author	John J. Suschak Joseph W. Golden Collin J. Fitzpatrick Charles J. Shoemaker Catherine V. Badger Connie S. Schmaljohn Aura R. Garrison
author_facet	John J. Suschak Joseph W. Golden Collin J. Fitzpatrick Charles J. Shoemaker Catherine V. Badger Connie S. Schmaljohn Aura R. Garrison
author_sort	John J. Suschak
title	A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice
title_short	A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice
title_full	A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice
title_fullStr	A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice
title_full_unstemmed	A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice
title_sort	cchfv dna vaccine protects against heterologous challenge and establishes gp38 as immunorelevant in mice
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/202859103c404a889b8935a4b09444ed
work_keys_str_mv	AT johnjsuschak acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT josephwgolden acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT collinjfitzpatrick acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT charlesjshoemaker acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT catherinevbadger acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT conniesschmaljohn acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT aurargarrison acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT johnjsuschak cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT josephwgolden cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT collinjfitzpatrick cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT charlesjshoemaker cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT catherinevbadger cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT conniesschmaljohn cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT aurargarrison cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice
_version_	1718378974055235584

A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice

Ejemplares similares